Cognition Therapeutics

CogRx is discovering and developing new drugs to halt disease progression and improve symptoms in neurodegenerative disorders. CogRx discovered small molecule drugs that can dramatically reduce toxic beta-amyloid oligomer binding to receptor proteins on the brain cells at synapses.  CogRx drugs reverse the memory loss in Alzheimer’s mouse models after 1 month and sustain this memory improvement for 6 months.  These drugs represent the first ever reported to target these toxic proteins and receptors and stop their effects on memory.

Back to Companies

Hank Safferstein
Susan Catalano
CSO & Co-Founder